title: A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer.
authors.affiliation: NHS Centre for Reviews and Dissemination, University of York, UK.
authors.forename: C
authors.initials: C
authors.lastname: Forbes
authors.forename: J
authors.initials: J
authors.lastname: Wilby
authors.forename: G
authors.initials: G
authors.lastname: Richardson
authors.forename: M
authors.initials: M
authors.lastname: Sculpher
authors.forename: L
authors.initials: L
authors.lastname: Mather
authors.forename: R
authors.initials: R
authors.lastname: Riemsma
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004317:Doxorubicin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D013222:State Medicine; D013534:Survival; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin